MGNX
MACROGENICS INCCompany Information
- Company Name
- MACROGENICS INC
- CIK
- CIK0001125345
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- MGNX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MGNX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-20
- Last sale
- 2026-08-19
- Shares purchased (TTM)
- 49,500
- Shares sold (TTM)
- 31,105
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 46,367,878
- Shares outstanding
- 63,594,453
- Ownership
- 72.91%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 4.27%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 114 | 67 | 57 | 80 | 131 | 146 | 183 | 180 | 84 | 80 | 101 | 90 | ||||||
| Investments | 59 | 88 | 133 | 66 | 46 | 9 | 19 | 21 | 56 | 104 | 129 | 167 | ||||||
| Accounts Receivable Net Current | 25 | 10 | 13 | 69 | 13 | 11 | 4 | 9 | 6 | 7 | 10 | 25 | ||||||
| Inventory Net | - | 9 | 8 | 9 | 9 | 9 | 0 | 3 | 1 | 1 | 1 | 1 | ||||||
| Other Receivables Net Current | 120 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 4 | 8 | 9 | 8 | 7 | 8 | 12 | 10 | 9 | 10 | 10 | 9 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets Current | 322 | 183 | 220 | 232 | 205 | 182 | 217 | 222 | 157 | 203 | 251 | 291 | ||||||
| Property Plant And Equipment Net | 2 | 11 | 13 | 14 | 15 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | ||||||
| Operating Lease Right Of Use Asset | 21 | 22 | 23 | 23 | 24 | 24 | 25 | 22 | 23 | 23 | 24 | 25 | ||||||
| Other Assets Noncurrent | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 345 | 218 | 257 | 271 | 245 | 225 | 262 | 264 | 201 | 248 | 298 | 340 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 4 | 5 | 6 | 5 | 7 | 5 | 7 | 5 | 11 | 6 | 3 | ||||||
| Accrued Liabilities Current | 30 | 18 | 22 | 23 | 21 | 28 | 29 | 25 | 24 | 18 | 24 | 25 | ||||||
| Contract With Customer Liability Current | 56 | 68 | 11 | 10 | 8 | 16 | 16 | 23 | 24 | 23 | 22 | 19 | ||||||
| Operating Lease Liability Current | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 109 | 96 | 43 | 44 | 39 | 55 | 56 | 59 | 58 | 56 | 56 | 51 | ||||||
| Contract With Customer Liability Noncurrent | 0 | 0 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 59 | 64 | ||||||
| Operating Lease Liability Noncurrent | 30 | 31 | 32 | 32 | 32 | 32 | 33 | 29 | 30 | 30 | 30 | 30 | ||||||
| Other Liabilities Noncurrent | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 303 | 197 | 201 | 204 | 199 | 145 | 146 | 144 | 143 | 142 | 146 | 146 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital Common Stock | 1,304 | 1,302 | 1,299 | 1,297 | 1,293 | 1,289 | 1,285 | 1,274 | 1,268 | 1,261 | 1,255 | 1,250 | ||||||
| Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,262 | -1,281 | -1,244 | -1,230 | -1,247 | -1,211 | -1,170 | -1,154 | -1,211 | -1,155 | -1,103 | -1,057 | ||||||
| Stockholders Equity | 43 | 21 | 56 | 67 | 47 | 79 | 116 | 120 | 58 | 106 | 153 | 194 | ||||||
| Liabilities And Stockholders Equity | 345 | 218 | 257 | 271 | 245 | 225 | 262 | 264 | 201 | 248 | 298 | 340 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | ||||||
| Shares Outstanding | 64 | 64 | 63 | 63 | 63 | 63 | 63 | 63 | 63 | 63 | 62 | 62 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMACROGENICS INC (MGNX) — SEC Financial Statements & Analysis
MACROGENICS INC (MGNX) is a pharmaceutical preparations company, incorporated in DE. MACROGENICS INC trades on Nasdaq as: MGNX. MACROGENICS INC (MGNX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, MACROGENICS INC carries a market cap of $293.81M, a P/E ratio of -20.13x, a P/B ratio of 6.85x, a P/S ratio of 1.61x, an enterprise value of $179.90M, and an EV/EBITDA multiple of -6.34x. On profitability, it posts a gross margin of 103.57%, an operating margin of -18.73%, a net margin of -7.97%, a Return on Equity (ROE) of -32.61%, a Return on Assets (ROA) of -4.94%, and a Return on Invested Capital (ROIC) of -378.08%. Per share, it reports EPS of $-0.23, diluted EPS of $-0.23, free cash flow per share of $-1.03, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 21.93% year-over-year, net income growth of -59.91% year-over-year, and EPS growth of -60.20% year-over-year. On the balance sheet, it maintains a current ratio of 2.96x, a quick ratio of 2.92x, working capital of $212.87M, a debt-to-equity ratio of 7.06x, a debt ratio of 0.88, an interest coverage ratio of -2.72x, free cash flow of $-65.54M (TTM), and net debt of $-113.91M. Figures sourced from SEC EDGAR.
- Market Cap
- $293.81M
- P/E TTM
- -20.13x
- EPS TTM
- $-0.23
- P/B TTM
- 6.85x
- ROE TTM
- -32.61%
- ROA TTM
- -4.94%
- Debt To Equity
- 7.06x
- Free Cash Flow TTM
- $-65.54M
- Net Revenue TTM Growth 1Y
- 21.93%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is MACROGENICS INC in?
MACROGENICS INC (MGNX) operates in the Pharmaceutical Preparations industry.
What exchange does MGNX trade on?
MACROGENICS INC (MGNX) trades on the Nasdaq.
Where is MACROGENICS INC incorporated?
MACROGENICS INC is incorporated in DE.
When was MACROGENICS INC (MGNX)'s most recent SEC filing?
MACROGENICS INC (MGNX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is MGNX's market cap?
MACROGENICS INC (MGNX) has a market capitalization of $293.81M as of 2026-06-30.
What is MGNX's EPS (earnings per share)?
MACROGENICS INC (MGNX)'s trailing twelve month EPS is $-0.23 as of 2026-06-30.
What is MGNX's ROE (return on equity)?
MACROGENICS INC (MGNX)'s trailing twelve month Return on Equity (ROE) is -32.61% as of 2026-06-30.
What is MGNX's ROA (return on assets)?
MACROGENICS INC (MGNX)'s trailing twelve month Return on Assets (ROA) is -4.94% as of 2026-06-30.
What is MGNX's ROIC (return on invested capital)?
MACROGENICS INC (MGNX)'s trailing twelve month Return on Invested Capital (ROIC) is -378.08% as of 2023-12-31.
What is MGNX's EV/EBITDA?
MACROGENICS INC (MGNX)'s trailing twelve month EV/EBITDA is -6.34x as of 2026-06-30.